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Abstract Several studies have reported a decline in inci-
dence of dementia which may have large implications for
the projected burden of disease, and provide important
guidance to preventive efforts. However, reports are con-
flicting or inconclusive with regard to the impact of gender
and education with underlying causes of a presumed
declining trend remaining largely unidentified. The Alz-
heimer Cohorts Consortium aggregates data from nine
international population-based cohorts to determine
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changes in the incidence of dementia since 1990. We will
employ Poisson regression models to calculate incidence
rates in each cohort and Cox proportional hazard regression
to compare 5-year cumulative hazards across study-specific
epochs. Finally, we will meta-analyse changes per decade
across cohorts, and repeat all analysis stratified by sex,
education and APOE genotype. In all cohorts combined,
there are data on almost 69,000 people at risk of dementia
with the range of follow-up years between 2 and 27. The
average age at baseline is similar across cohorts ranging
between 72 and 77. Uniting a wide range of disease-
specific and methodological expertise in research teams,
the first analyses within the Alzheimer Cohorts Consortium
are underway to tackle outstanding challenges in the
assessment of time-trends in dementia occurrence.
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Introduction
It is estimated that approximately 47 million people are
currently living with dementia, making it a leading cause of
dependence and disability worldwide [1]. Because of a
rapidly aging population, this number is predicted to have
nearly doubled by 2040 [2]. Consequently the social and
economic burdens of dementia are expected to substan-
tially increase [3]. Yet, the projected burden of disease
could be significantly lower if improvements in life con-
ditions and health care over the last decades have had a
beneficial effect on reducing risk of dementia. Indeed,
recent studies in North America and Europe have reported
a decline in the incidence of dementia over the last
20 years, up to 20% reduction per decade [4–8]. However,
the underlying causes have not been determined, and dis-
crepancies in described trends between sexes, and across
different ethnicities and levels of education warrant further
exploration [9, 10].
Valid assessment of time trends in the incidence of a
disease calls for careful monitoring of it within the general
population, in a consistent manner over a prolonged period
of time. Population-based cohort studies are generally
designed to establish determinants of disease, using con-
sistent methodology throughout the course of data collec-
tion. The wide range of routinely collected data within
these studies allows for exploration of effect modifiers (e.g.
genotype or sex), as well as various potential underlying
causes, such as changes in cardiovascular risk manage-
ment, comorbidity (e.g. stroke), and level of education.
Worldwide, however, only a limited number of studies
exist, that are carried out in unselected populations and
provide the infrastructure and decade-long follow-up
duration necessary to determine trends in dementia inci-
dence. Power and precision of these individual studies are
not always sufficient to answer the research questions
outlined above. We therefore aim to jointly analyse avail-
able long-term population-based data seeking confirmation
for any time trends in dementia occurrence and importantly
identify determinants of such trends. The results will have
important implications for informing public health policy
focused on dementia reduction.
Materials and methods
The Alzheimer Cohorts Consortium
The Alzheimer Cohorts Consortium is a collaboration of
nine prospective cohorts studies from the United States and
Europe including: the Age, Gene/Environment Suscepti-
bility (AGES)-Reykjavik Study, the Atherosclerosis Risk
in Communities (ARIC) study, the Cardiovascular Health
Study (CHS), the Cognitive Function and Ageing Studies
(CFAS), the Framingham Heart Study (FHS), the
Gothenburg population studies, the Personnes Age´es QUID
(PAQUID) study, the Rotterdam Study, and the Three-City
Study (3C). All cohorts are population-based and comprise
of prospectively collected data on dementia (and in most
studies information on clinical subtypes), in addition to
genotyping, and extensive (cardiovascular) phenotyping.
Description of cohorts
A summary of the key characteristics of each cohort are
presented in Table 1. Across the cohorts there are more
than 70,000 individuals of whom around 6300 have
developed dementia to date. Briefly, the AGES-Reykjavik
Study represents a sample drawn from the population-based
Reykjavik Study [11]. The original Reykjavik Study
comprised a random sample of 30,795 men and women
born between 1907 and 1935 and living in Reykjavik in
1967. Between 1967 and 1996, six examinations were
conducted in six sub-cohorts, and 5764 survivors of the
original cohort were re-examined for the AGES-Reykjavik
study between 2002 and 2006. The ARIC study is a pop-
ulation-based prospective cohort study of cardiovascular
disease and its risk factors [12]. Chosen by probability
sampling from four U.S. communities including Winston-
Salem (NC), Jackson (MS), Minneapolis (MN), and Bal-
timore (MD), the study included 15,792 individuals aged
45–64 years at study baseline in 1987–1989. Participants
completed four clinic examinations, conducted 3 years
apart, up till 1998, and undergo annual follow-up for
clinical events. Between 2011 and 2013, all surviving
ARIC participants were invited to a 5th visit (ARIC
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Neurocognitive Study (ARIC-NCS), when a comprehen-
sive dementia assessment was performed. The CHS is a
population-based cohort study of risk factors for cardio-
vascular disease in adults aged 65 years and older,
recruited in 1989–1990 from random samples of the
Medicare lists in four U.S. field centers, namely Sacra-
mento (CA), Hagerstown (MD), Winston-Salem (NC), and
Pittsburgh (PA) [13] The original predominantly white
cohort of 5888 persons was expanded by enrolment of 687
African-Americans in 1992–1993. Participants completed
standardized clinical examinations and questionnaires at
study baseline and at annual follow-up visits until 1999.
Ongoing follow-up for clinical events occurs by phone
every 6 months thereafter. The CFAS comprise two sepa-
rate population-based studies in three sites from the origi-
nal Medical Resource Council CFAS (Cambridgeshire,
Newcastle and Nottingham), conducted 20 years apart in
the UK [5]. The samples includes individuals aged
65 years and over regardless of residential status (i.e.
persons living in the community as well as institutions).
The first study, CFAS I, recruited in 1990-1993
(N = 7635) with a 2-year follow-up in of 20% of partici-
pants (n = 900) in 1993–1995. A second, comparison
study, CFAS II, was initiated two decades later, between
2008 and 2011 (N = 7796) with a 2-year follow-up
screening (n = 5288) in 2011–2013. Identical methods
were used in CFAS I and CFAS II with the exception of a
two-stage enrolment (separate screening and assessment
interview) utilized in CFAS I and a one-stage enrolment for
CFAS II (single screening and assessment interview) [14].
The FHS began in 1948 with the recruitment of an original
cohort of 5209 men and women who were aged 28–62 at
study entry [15]. In 1971, a second generation of study
participants, including 5124 children and spouses of chil-
dren of the original cohort were enrolled [16]. Enrolment
of the third generation cohort of 4095 children of offspring
cohort participants began in 2002 [17]. Clinic follow-up
examinations take place approximately every two year for
the original cohort and approximately every 4 years for the
Offspring and Third Generation cohorts. In addition, the
cohorts are under continuous surveillance for disease
endpoints, such as myocardial infarction, stroke, and
dementia. The Gothenburg population studies consist of
data from four studies which recruited individuals repre-
sentative of the Swedish population [18]. These include
Kvinnounderso¨kningen (KVUS), a study of 1462 women
aged 38–60 who have been followed since 1968; the H70
study, which includes representative samples of 70-year-
olds born 1906–1907 (N = 414), recruited 1976–1977, and
followed until death, and 1930 (N = 522), recruited
2000–2001 and followed until now, the H85 study, which
includes samples of 85-year-olds born 1901–1902
(N = 494), first examined in 1986 and followed until
death, and 1923–1924 (N = 571), first examined in
2008–2009 and followed until age 90; and the 95-plus
study that started in 1996 and by 2012 had recruited a total
of 950 individuals. The PAQUID cohort is a population-
based study in the southwest of France of 3777 individuals
aged 65 years or older recruited in 1988 [19]. There have
been nine waves of data collection at 1, 3, 5, 8, 10, 13, 15,
17, 20, 23, 25, and 27 years after the baseline assessment.
The RS is a prospective population-based cohort study
comprising 14,926 subjects aged 45 years or older [20].
Baseline data of 7983 participants were collected between
Table 1 Description of the cohorts included in the Alzheimer Cohorts Consortium
Study AGES-
Reykjavik
ARIC
NCS
CFAS
I/II
CHS Framingham
Heart Study
Gothenburg
studies
PAQUID Rotterdam
Study
Three-City
Study
Country Iceland USA UK USA USA Sweden France Netherlands France
Study baseline 2002 2011–2013 1991/
2008
1991 1990 1990 1988 1990 1999
Family-based No No No No Yes No No No No
Study sites 1 4 3/3 4 1 1 1 1 3
Dementia
follow-up
(years)
14 5a 2/2 18 25 25 27 25 16
Diagnosis of
dementia
DSM-IV DSM-V DSM-
IIIR
DSM-IV DSM-IV DSM-IIIR DSM-IIIR DSM-IIIR DSM-IV
Diagnosis of AD NINCDS-
ADRDA
NIA-AA N/A NINCDS-
ADRDA
NINCDS-
ADRDA
NINCDS-
ADRDA
NINCDS-
ADRDA
NINCDS-
ADRDA
NINCDS-
ADRDA
AGES Age, Gene/Environment Susceptibility, ARIC-NCS Atherosclerosis Risk in Communities Neurocognitive Study, CFAS Cognitive
Function and Ageing Studies, CHS Cardiovascular Health Study, PAQUID Personnes Age´es QUID, AD Alzheimer’s disease, N/A not available
aEfforts to work-up recent incident dementia cases are ongoing as of January 2017
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1990 and 1993, with subsequent cohort expansions in 2000
(3011 individuals) and 2006 (3236 individuals). Partici-
pants have been examined once every 4 years. In addition,
the entire cohort is continuously under surveillance for
disease outcomes through linkage of electronic medical
records with the study database. The 3C is a longitudinal
population-based study of the relation between vascular
diseases and dementia in persons aged 65 years and older
[21]. Between 1999 and 2001, a total of 9294 non-insti-
tutionalized persons were recruited from the electoral rolls
of three French cities: Bordeaux (South-West), Dijon
(North-East) and Montpellier (South-East). Participants
have been re-examined every 2 years.
Ethics
All participating studies have ethical approval, and all
subjects (or their nominated representative) provided
written informed consent.
Dementia assessment
The primary outcome is all-cause dementia and this is
assessed in all cohorts (Table 1). The secondary outcome is
diagnoses of Alzheimer’s disease (AD), the most common
clinical subtype. Methods for dementia diagnosis varied
between cohorts, but are consistently applied in each cohort
throughout the study period. An exception is CHS, in
which participants are re-examined more frequently from
2002 onwards (i.e. annually) compared to before diagnosis
of dementia and is based on change in cognition and
function from previous visits.
Defining epochs
One option for assessing trend over time is to define units
of time based on the same calendar years across cohorts.
This method makes it easy to combine results across
cohorts, but ignores the fact that each study has its own
pattern of examination cycles and therefore risks bringing
in more biases based on study design. To avoid this, we
choose to define units of time, or epochs, specific to each
study based on each interview wave. This allows us to take
full advantage of all available data in each study, maximize
the person-years available and also, by using the median
time since beginning of first epoch (as described in more
detail below in the statistical analysis section), we can
compare trends over the years across all the cohorts.
Requirements for defining an epoch are: (1) start at or close
to an examination cycle, (2) non-overlapping with previous
or subsequent epoch, and (3) at least 5 years in length.
Participants need to be 60 years or over, and free of
dementia at the start of the epoch to be included. All
cohorts have follow-up for at least two epochs, except for
AGES, in which only a baseline epoch has sufficient fol-
low-up.
Statistical analysis
All analyses are currently being performed in individual
cohorts and results will be meta-analysed when appropri-
ate. Demographic characteristics of each cohort are sum-
marized using means with standard deviation (SD) for
continuous measures and frequencies for categorical mea-
sures. The calendar time-window of the present analyses is
restricted to 1990–2015 to allow for assessment of inci-
dence rates and time trends across the same time-period in
all cohorts.
Five-year incidence rates (IRs) with 95% confidence
intervals (CI) are being calculated using age-adjusted
Poisson regression models. Groups are first stratified by
5-year age-groups and then additionally by sex. IRs are
reported for the middle age within each age group, e.g. 62.5
for the (60–65) age group, 67.5 for the (65–70) age group,
etcetera. A participant is included in a particular age group
if they were dementia-free at start of the age group cate-
gory. Since all the cohorts have repeated visits with par-
ticipants, when data was available, a single person could
contribute to IRs of multiple age groups. To account for
this, we employ robust sandwich estimators to calculate the
95% CI around the IRs.
Five-year cumulative hazards and hazard ratios are be-
ing assessed individually in each cohort and not combined
across studies because of differing timing of examinations.
Non-overlapping epochs are defined based on examination
cycles and are specific to each cohort. Five-year cumula-
tive hazard and hazard ratios (HRs) are being calculated
using a Cox proportional hazard regression model and
adjusted for age and sex in non-stratified models using a
robust sandwich estimator for covariance structure [22].
Participants who did not experience a dementia diagnosis
are censored at the last date they were known to be free of
dementia, or 5 years after the beginning of the epoch,
whichever was sooner. Hazard ratios are being computed
for each epoch as compared to the first epoch followed by
trend per decade. We do this by assigning to each epoch an
index value equal to median time in years since the
beginning of the first epoch. For example, if epoch 1 was
1995–1999 and epoch 2 was 2000–2005 then the index
variable would be 2.5 and 7.5 respectively. The index
variable is then used in the Cox proportional hazard
regression to assess a linear change in hazard of dementia
over the epochs or linear trend. To ensure the analyses are
identical across cohorts, statistical code using both SPSS
and SAS was developed and tested using the Rotterdam
L. B. Chibnik et al.
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Study dataset to ensure results matched between statistical
software programs and then provided to each cohort for
analyses. All analyses are currently being performed using
either SPSS version 23.0 (IBM Corp, Armonk, NY, USA)
or SAS 9.4 (Cary, NC, USA).
Results
Descriptions of all cohorts are summarized in Table 1. In
all cohorts combined there is data on almost 69,000 people
at risk of dementia with the range of follow-up years
between 2 and 27. The average age at baseline is similar
across cohorts ranging between 72 and 77 (Table 2). Each
cohort is made up of[ 50% females, ranging from 56.8%
in FHS to 76.3% in the Gothenburg studies (Table 2). All
cohorts collect information on incident dementia and all
but one cohort (CFAS I/II) also collecting information on
incident AD.
Discussion
Several of the cohorts within the Alzheimer Cohorts
Consortium have previously published data on time trends
in the prevalence and incidence of dementia [4, 5, 7, 8]. In
this collaboration, we aim to reproduce these findings using
consistent analytical techniques, and harmonise results
across the individual cohort studies to identify underlying
trends and investigate subgroups of interest (e.g. stratifi-
cation by gender) and effect modifiers. The close collab-
oration between cohorts in the consortium, along with the
high-quality study design and data collection methods
facilitate these analyses of incidence trends over the past
three decades.
Cohort enrolment, resampling, and survival bias
Most cohorts contributing data to these analyses use a
closed-cohort design with single enrolment, while two of
the cohorts, FHS and the Rotterdam Study, are expanded
during the study period, including additional individuals
from the source population and one set of cohorts, CFAS I
and CFAS II is composed of two comparison cohorts each
with a follow-up assessment. Single enrolment in closed
cohorts will limit the number of comparable individuals
within the same age range, as the cohort on average
becomes older over time. We intend to utilize the full
potential of this collaboration by including all available
data, i.e. expansion cohorts as well as the originally defined
cohorts. On a participant level, we allow a single partici-
pant to be included in multiple epochs as long as they are
free of dementia at the start of the epoch. This can lead to
underestimation of the standard error and thus we utilize
robust standard error estimates. Restricting non-demented
participants to only a single epoch, such as the epoch of
their first examination, would deplete the number of par-
ticipants susceptible to dementia over time. This would
mean that individuals at high risk would be underrepre-
sented at later time points. Such selection bias could result
in underestimation of the incidence rates and cumulative
hazards in more recent years. Conversely, mortality rates
have dropped substantially over the past decades, and the
increase in life-expectancy renders more people susceptible
Table 2 Demographics of the cohorts included in the Alzheimer Cohorts Consortium
Study AGES-
Reykjavik
ARIC
NCS
CFAS
I/II
CHS Framingham Heart
Study
Gothenburg
studies
PAQUID Rotterdam
Study
Three-City
Study
At risk of
dementia
5722 6538 7635/
7762
2798 8586 3024 2997 11,044 8250
Mean age (years) 77.0 75.8 75.0/
76.4
74.7 72.1 77.3 75.3 72.0 74.0
Women (%) 57.7 58.8 61.6/
56.1
59.1 56.8 76.3 58.0 58.5 61.3
Caucasian
ethnicity (%)
100 76.1 99.1/
97.2
89.5 100 100 NCb 98.0 100
Incident
dementiaa
250 344 250/
250
680 800 700 940 1400 950
Incident ADa 150 72 N/A 590 510 300 730 1100 650
AGES Age, Gene/Environment Susceptibility, ARIC-NCS Atherosclerosis Risk in Communities Neurocognitive Study, CFAS Cognitive
Function and Ageing Studies, CHS Cardiovascular Health Study, PAQUID Personnes Age´es QUID, AD Alzheimer’s disease, N/A Not Available
aApproximation of total number of individuals with dementia per cohort at time of press
bNot collected
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to dementia these days than in earlier years. This survival
bias may cause underestimation of a declining trend in the
incidence of dementia.
All-cause dementia as a primary outcome measure
Distinguishing clinical AD from other dementia subtypes
such as vascular dementia or dementia with Lewy bodies
has proven challenging in light of the multiple pathologies
co-occurring with increased age in the majority of cases
with dementia [23–26]. This is particularly troubling as the
incidence of dementia increases steeply with age, with the
vast majority of dementia cases occurring after 70 years of
age. Studies of dementia and sporadic AD focused on older
aged samples consequently recruit individuals in whom a
large number of factors (e.g. neurodegenerative and vas-
cular) contribute to cognitive decline and dementia, ham-
pering accurate diagnosis of dementia subtypes. Not only
does this burden etiological research, it could also con-
tribute to heterogeneity in dementia diagnoses between
cohorts. In addition, diagnosis of all-cause dementia is less
susceptible to changes in clinical subtyping of dementia
that may have occurred over time. For these reasons, the
focus of the analysis is on all-cause dementia, which can be
more reliably defined across cohorts. The wide age range of
the unselected populations guarantees generalizability to
understudied elderly individuals, and reflects the full
spectrum of the dementia burden in the population.
Dementia occurrence across cohorts
Despite many similarities in design and data collection
between the cohorts in this collaboration, there are also
factors that may lead to differences in baseline incidence
rates across the different cohorts. These include underlying
population traits (e.g. access to health care, socioeconomic
status, genetic make-up, and lifestyle), and variations in
methodology (e.g. re-examination interval, continuous
surveillance methods). For the most part these are likely to
remain constant over the course of the study period, and
although contributing to differences in baseline incidence,
arguably less likely to influence within study trends. Dif-
ferences in risk of mortality across cohorts, however, may
differentially affect the results, because of survival bias, as
described above. In addition, differences in the diagnosis of
dementia across cohorts and region-specific changes in the
clinical assessment of dementia over time pose a challenge
to trend analysis. Lastly, all cohorts are embedded within
the general population, but cannot completely avoid vari-
ation in sampling strategies and inclusion rates. Moreover,
strategies for follow-up and disease surveillance vary,
potentially affecting attrition or diagnostic sensitivity,
which may hamper absolute risk estimates in particular.
Variation may, in part, be addressed by accounting for
genetic heterogeneity, further stratification when sample
size allows (e.g. for educational attainment, vascular dis-
ease burden), or use of more advanced statistical methods,
such as illness-death modelling to deal with death occur-
ring during the inter-examination interval.
Within the Alzheimer Cohorts Consortium nine
prospective population-based cohort studies leverage con-
scientiously collected data over a 25-year period with the
aim to determine trends in the incidence of dementia and to
unravel underlying causes. Uniting a wide range of disease-
specific and methodological expertise in research teams
within and beyond these cohorts, the first analyses within
the Alzheimer Cohorts Consortium are underway to tackle
outstanding challenges in the assessment of time-trends in
dementia occurrence.
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